Literature DB >> 19491104

Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease.

Lars M Ittner1, Yazi D Ke, Jürgen Götz.   

Abstract

In Alzheimer disease (AD) and frontotemporal dementia the microtubule-associated protein Tau becomes progressively hyperphosphorylated, eventually forming aggregates. However, how Tau dysfunction is associated with functional impairment is only partly understood, especially at early stages when Tau is mislocalized but has not yet formed aggregates. Impaired axonal transport has been proposed as a potential pathomechanism, based on cellular Tau models and Tau transgenic mice. We recently reported K369I mutant Tau transgenic K3 mice with axonal transport defects that suggested a cargo-selective impairment of kinesin-driven anterograde transport by Tau. Here, we show that kinesin motor complex formation is disturbed in the K3 mice. We show that under pathological conditions hyperphosphorylated Tau interacts with c-Jun N-terminal kinase- interacting protein 1 (JIP1), which is associated with the kinesin motor protein complex. As a result, transport of JIP1 into the axon is impaired, causing JIP1 to accumulate in the cell body. Because we found trapping of JIP1 and a pathological Tau/JIP1 interaction also in AD brain, this may have pathomechanistic implications in diseases with a Tau pathology. This is supported by JIP1 sequestration in the cell body of Tau-transfected primary neuronal cultures. The pathological Tau/JIP1 interaction requires phosphorylation of Tau, and Tau competes with the physiological binding of JIP1 to kinesin light chain. Because JIP1 is involved in regulating cargo binding to kinesin motors, our findings may, at least in part, explain how hyperphosphorylated Tau mediates impaired axonal transport in AD and frontotemporal dementia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491104      PMCID: PMC2742856          DOI: 10.1074/jbc.M109.014472

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.

Authors:  Della C David; Lars M Ittner; Peter Gehrig; Denise Nergenau; Claire Shepherd; Glenda Halliday; Jürgen Götz
Journal:  Proteomics       Date:  2006-12       Impact factor: 3.984

2.  JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport.

Authors:  Gerardo Morfini; Gustavo Pigino; Györgyi Szebenyi; Yimei You; Sarah Pollema; Scott T Brady
Journal:  Nat Neurosci       Date:  2006-06-04       Impact factor: 24.884

Review 3.  Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?

Authors:  Jürgen Götz; Lars M Ittner; Stefan Kins
Journal:  J Neurochem       Date:  2006-06-19       Impact factor: 5.372

Review 4.  Axonal transport and Alzheimer's disease.

Authors:  Gorazd B Stokin; Lawrence S B Goldstein
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

Review 5.  Neuronal microtubules: when the MAP is the roadblock.

Authors:  Peter W Baas; Liang Qiang
Journal:  Trends Cell Biol       Date:  2005-04       Impact factor: 20.808

6.  APLIP1, a kinesin binding JIP-1/JNK scaffold protein, influences the axonal transport of both vesicles and mitochondria in Drosophila.

Authors:  Dai Horiuchi; Rosemarie V Barkus; Aaron D Pilling; Andrew Gassman; William M Saxton
Journal:  Curr Biol       Date:  2005-12-06       Impact factor: 10.834

7.  The N-terminal extracellular domain 23-60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1.

Authors:  Lars M Ittner; Daniela Koller; Roman Muff; Jan A Fischer; Walter Born
Journal:  Biochemistry       Date:  2005-04-19       Impact factor: 3.162

8.  Control of a kinesin-cargo linkage mechanism by JNK pathway kinases.

Authors:  Dai Horiuchi; Catherine A Collins; Pavan Bhat; Rosemarie V Barkus; Aaron Diantonio; William M Saxton
Journal:  Curr Biol       Date:  2007-07-19       Impact factor: 10.834

9.  Compound developmental eye disorders following inactivation of TGFbeta signaling in neural-crest stem cells.

Authors:  Lars M Ittner; Heiko Wurdak; Kerstin Schwerdtfeger; Thomas Kunz; Fabian Ille; Per Leveen; Tord A Hjalt; Ueli Suter; Stefan Karlsson; Farhad Hafezi; Walter Born; Lukas Sommer
Journal:  J Biol       Date:  2005-12-14

10.  Two binding partners cooperate to activate the molecular motor Kinesin-1.

Authors:  T Lynne Blasius; Dawen Cai; Gloria T Jih; Christopher P Toret; Kristen J Verhey
Journal:  J Cell Biol       Date:  2007-01-01       Impact factor: 10.539

View more
  70 in total

Review 1.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.

Authors:  Janet van Eersel; Yazi D Ke; Xin Liu; Fabien Delerue; Jillian J Kril; Jürgen Götz; Lars M Ittner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

Review 3.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

Review 4.  Tau in neurodegenerative disease.

Authors:  Yong-Lei Gao; Nan Wang; Fu-Rong Sun; Xi-Peng Cao; Wei Zhang; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2018-05

5.  CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation.

Authors:  Yazi D Ke; Gabriella Chan; Kristie Stefanoska; Carol Au; Mian Bi; Julius Müller; Magdalena Przybyla; Astrid Feiten; Emmanuel Prikas; Glenda M Halliday; Olivier Piguet; Matthew C Kiernan; Michael Kassiou; John R Hodges; Clement T Loy; John S Mattick; Arne Ittner; Jillian J Kril; Greg T Sutherland; Lars M Ittner
Journal:  J Biol Chem       Date:  2019-07-31       Impact factor: 5.157

6.  Tau and Axonal Transport Misregulation in Tauopathies.

Authors:  Benjamin Combs; Rebecca L Mueller; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

7.  Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.

Authors:  Mathew A Sherman; Michael LaCroix; Fatou Amar; Megan E Larson; Colleen Forster; Adriano Aguzzi; David A Bennett; Martin Ramsden; Sylvain E Lesné
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

Review 8.  The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease.

Authors:  Johanna L Crimins; Amy Pooler; Manuela Polydoro; Jennifer I Luebke; Tara L Spires-Jones
Journal:  Ageing Res Rev       Date:  2013-03-22       Impact factor: 10.895

9.  Animal models for Alzheimer's disease and frontotemporal dementia: a perspective.

Authors:  Jürgen Götz; Naeman N Götz
Journal:  ASN Neuro       Date:  2009-11-09       Impact factor: 4.146

Review 10.  Alzheimer's disease: insights from Drosophila melanogaster models.

Authors:  Aileen Moloney; David B Sattelle; David A Lomas; Damian C Crowther
Journal:  Trends Biochem Sci       Date:  2009-12-25       Impact factor: 13.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.